Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples